June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen
Author Affiliations & Notes
  • Christoph Grechenig
    Department of Ophthalmology and Optometry, Medizinische Universitat Wien, Wien, Wien, Austria
  • Gregor Sebastian Reiter
    Department of Ophthalmology and Optometry, Medizinische Universitat Wien, Wien, Wien, Austria
  • Sophie Riedl
    Department of Ophthalmology and Optometry, Medizinische Universitat Wien, Wien, Wien, Austria
  • Jennifer Arnold
    Marsden Eye Specialists, Parramatta, New South Wales, Australia
  • Robyn H Guymer
    Centre for Eye Research Australia Ltd, East Melbourne, Victoria, Australia
  • Bianca S Gerendas
    Department of Ophthalmology and Optometry, Medizinische Universitat Wien, Wien, Wien, Austria
  • Hrvoje Bogunovic
    Department of Ophthalmology and Optometry, Medizinische Universitat Wien, Wien, Wien, Austria
  • Ursula Schmidt-Erfurth
    Department of Ophthalmology and Optometry, Medizinische Universitat Wien, Wien, Wien, Austria
  • Footnotes
    Commercial Relationships   Christoph Grechenig, None; Gregor Reiter, None; Sophie Riedl, None; Jennifer Arnold, Allergan (F), Bayer (F), Novartis (F); Robyn Guymer, Apellis (F), Bayer (F), Genentech (F), Novartis (F), Roche (F); Bianca S Gerendas, IDx, LLC (F), Novartis (C); Hrvoje Bogunovic, None; Ursula Schmidt-Erfurth, Genentech (C), Heidelberg Engineering (C), Kodiak (C), Novartis (C), RetInSight (C), Roche (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 104. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christoph Grechenig, Gregor Sebastian Reiter, Sophie Riedl, Jennifer Arnold, Robyn H Guymer, Bianca S Gerendas, Hrvoje Bogunovic, Ursula Schmidt-Erfurth; Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen. Invest. Ophthalmol. Vis. Sci. 2021;62(8):104.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate associations between residual subretinal fluid (SRF) volumes, quantified using artificial intelligence (AI) and treatment outcomes in a SRF-tolerant treat and extend (T&E) anti-VEGF regimen in neovascular age-related macular degeneration (nAMD).

Methods : In this post-hoc analysis, patients enrolled in the prospective, multicenter FLUID study and randomized in a SRF-tolerant T&E regimen were examined by spectral-domain optical coherence tomography (SD-OCT) imaging and tested for best-corrected visual acuity (BCVA) over a 24 months follow-up. Validated AI-based image analysis tools were used to quantify SRF and intraretinal fluid (IRF) volumes on SD-OCT. 375 visits of 98 patients of the SRF tolerant arm were divided into two subgroups: Extended intervals despite residual SRF, and visits with extension without fluid. BCVA change at the follow-up visit was compared between the groups. The associations of SRF volumes in the central 1mm and 6mm as well as treatment intervals with BCVA change were estimated using generalized linear mixed models.

Results : At visits with extended intervals despite residual SRF an increase in SRF was associated with a significant BCVA reduction at the next visit in the central 1mm (-0.138 letters/nl SRF; p=0.014) and the total 6mm (-0.024 letters/nl SRF; p=0.049). Visits with extended intervals despite residual SRF had significantly higher SRF volumes in the central 6mm (p=0.002) at the following visit, and showed a trend in the central 1mm (p=0.061). A statistically significantly negative association between increased treatment interval and change in BCVA was found for residual SRF in 1 and 6mm (-0.250 and -0.233 letter/week interval, respectively, both p<0.001).

Conclusions : A fully automated quantitative analysis of extended visits despite residual SRF demonstrated increasing SRF volumes associated with BCVA loss at the following visit. This association contributes to our understanding of the quantitative impact of residual SRF volumes on visual function and highlights the importance of precise and quantitative measurements of fluid volumes as the field determines the most efficacious regimens for individualizing treatment for nAMD with anti-VEGF therapies.

This is a 2021 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×